Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic significance of mucinous histology in left‑sided metastatic colorectal cancers with wild‑type RAS and evaluation of backbone chemotherapy regimens.
Arikan R, Atci MM, Ay S, Ayhan M, Demircan NC, Telli TA, Çelebi A, Yaşar A, Işik S, Celikel C, Balvan O, Bayoglu IV, Kostek O, Dane F, Yumuk PF. Arikan R, et al. Among authors: kostek o. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795. eCollection 2023 May. Oncol Lett. 2023. PMID: 37123028 Free PMC article.
Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer.
Köstek O, Demircan NC, Gökyer A, Küçükarda A, Sunal BS, Hacıoğlu MB, Eslame H, Solak S, Yılmaz E, Uzunoğlu S, Tunçbilek N, Çiçin I, Erdoğan B. Köstek O, et al. Clin Transl Oncol. 2019 Nov;21(11):1510-1517. doi: 10.1007/s12094-019-02079-x. Epub 2019 Mar 28. Clin Transl Oncol. 2019. PMID: 30924091
Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey.
Bekir Hacioglu M, Kostek O, Karabulut S, Tastekin D, Sezgin Goksu S, Alandag C, Akagunduz B, Bilgetekin I, Caner B, Bilgehan Sahin A, Yildiz B, Kose F, Kaplan MA, Gulmez A, Dogan E, Can Guven D, Gurbuz M, Ergun Y, Karaagac M, Gokcen Demiray A, Turker S, Sakalar T, Ozkul O, Telli TA, Sahin S, Kilickap S, Bilici A, Erdogan B, Cicin I. Bekir Hacioglu M, et al. Among authors: kostek o. J BUON. 2020 Jul-Aug;25(4):1897-1903. J BUON. 2020. PMID: 33099930 Free article.
Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?
Ayhan M, Turan N, Köstek O, Tufan G, Tataroğlu Özyükseler D, Odabas H, Sakin A, Turan M, Sürmeli H, Yıldırım ME. Ayhan M, et al. Among authors: kostek o. Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670. Epub 2020 Oct 22. Curr Probl Cancer. 2021. PMID: 33129567
96 results